文献速递慢性静脉疾病静脉血栓栓塞

髂静脉支架术后早期血栓形成与疾病严重程度及抗凝类型相关

Early thrombosis after iliac stenting for venous outflow occlusion is related to disease severity and type of anticoagulation.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2021-03-02

该回顾性研究纳入2010至2020年因慢性髂静脉/下腔静脉完全闭塞行支架置入的106例患者,发现3个月内支架闭塞率25.5%,且IV型病变和高凝状态独立增加早期血栓风险,而低分子肝素使用超过10天显著降低再闭塞风险。

要点

  • 完全闭塞静脉流出道支架术后3个月内早期再闭塞率高达25.5%。
  • IV型病变和高凝状态是早期支架血栓的独立危险因素。
  • 低分子肝素抗凝超过10天与早期再闭塞风险显著降低相关。

核心结论

  • 完全闭塞静脉流出道再通后支架置入的早期再闭塞率高,病变范围广和高凝状态增加风险,低分子肝素超过10天可降低风险。

研究设计与样本

  • 回顾性研究,纳入2010至2020年因慢性股总静脉、髂静脉和/或下腔静脉完全闭塞行支架置入的106例患者。

主要发现

  • 3个月内支架段闭塞率为25.5%,一期通畅率3个月74.5%、12个月63.9%、3年58.5%,二期通畅率3个月93.4%、3年和5年76.1%。
  • 多因素分析显示IV型闭塞(OR 4.596,95%CI 1.424-18.109)和高凝状态(OR 3.835,95%CI 1.207-12.871)与早期支架血栓独立相关。
  • 低分子肝素使用超过10天与早期再闭塞风险显著降低独立相关(OR 0.012,95%CI 0.001-0.130)。

关键数值与推荐

  • IV型病变(多节段静脉流出道完全闭塞)患者早期再闭塞风险显著高于III型(OR 4.596,95%CI 1.424-18.109)。
  • 高凝状态患者早期再闭塞风险显著增加(OR 3.835,95%CI 1.207-12.871)。
  • 低分子肝素使用超过10天与早期再闭塞风险显著降低相关(OR 0.012,95%CI 0.001-0.130)。

临床怎么用

  • 对完全闭塞静脉流出道行支架置入时,应评估病变类型和高凝状态以识别早期血栓高危患者。
  • 术后可考虑使用低分子肝素超过10天以降低早期再闭塞风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stenting of the iliac venous system is often performed for symptomatic obstruction, with high patency rates reported. However, patients with post-thrombotic disease and those with more extensive obstruction have experienced poorer outcomes, including a higher rate of early post-stent thrombosis. In the present study, we examined the outcomes of patients with complete venous outflow occlusion. We focused on the variables associated with early post-stenting thrombosis to identify opportunities to reduce its incidence. METHODS: From 2010 to 2020, the patients who had undergone stenting for chronic obstruction of the common femoral vein, iliac veins, and/or inferior vena cava were retrospectively reviewed. The pre- and intraoperative imaging studies were examined to identify those who had had total occlusion of one venous outflow segment (type III disease) or multiple venous outflow segments (type IV disease). The patient characteristics and procedural and post-stent variables were recorded. The post-procedure follow-up visits and imaging studies were reviewed to determine stent patency and thrombotic complications. Key variables were studied to determine their association with early stent reocclusion. RESULTS: A total of 106 patients were identified, including 43 with type III (40.6%) and 63 with type IV (59.4%) disease. The mean patient age was 49.8 ± 13.7 years, and the mean stented length was 177.3 ± 63 mm. Stainless steel Wallstents were used solely in 44% of the cases, with a variety of nitinol stents used in the remainder. Femoral vein inflow was minimally diseased in 50% of the cases, moderately diseased in 26%, and severely diseased or occluded in 24%. Antiplatelet medications were prescribed after intervention for 52.8% and anticoagulation medication for 95.3% of the patients. Occlusion of the stented segment occurred within 3 months in 25.5%. Primary patency was 74.5% at 3 months, 63.9% at 12 months, and 58.5% at 3 years. Secondary patency was 93.4% at 3 months and 76.1% at 3 and 5 years. Univariate analysis of variables related to early stent thrombosis identified the presence of a hypercoagulable state, type IV obstruction, and the type of anticoagulation used after stenting were associated with early stent thrombosis. On multivariate analysis, each of these variables was independently associated with early stent thrombosis. The presence of type IV obstruction (odds ratio [OR], 4.596; 95% confidence interval [CI], 1.424-18.109) or a hypercoagulable state (OR, 3.835; 95% CI, 1.207-12.871) was associated with significantly greater odds of reocclusion than was class III obstruction and no hypercoagulable state. Treatment with low-molecular-weight heparin for >10 days was associated with significantly lower odds (OR, 0.012; 95% CI, 0.001-0.130) of reocclusion. CONCLUSIONS: Patients who require recanalization of a completely occluded venous outflow tract before stenting have a high rate of early reocclusion. Patients with more extensive occlusion and a hypercoagulable state have greater odds of reocclusion. Treatment with low-molecular-weight heparin for >10 days reduced the odds of early reocclusion.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Marston WA, Browder SE, Iles K, et al. Early thrombosis after iliac stenting for venous outflow occlusion is related to disease severity and type of anticoagulation. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 33667740. doi:10.1016/j.jvsv.2021.02.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。